Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:04:09 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:VCYT from 2023-05-04 to 2024-05-03 - 40 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 17:00U:VCYTNews ReleaseVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024
2024-04-22 08:30U:VCYTNews ReleaseNew Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
2024-04-16 08:30U:VCYTNews ReleaseVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
2024-02-27 17:55U:VCYTNews ReleaseVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
2024-02-22 16:05U:VCYTNews ReleaseVeracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
2024-02-21 17:00U:VCYTNews ReleaseVeracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-02-08 08:00U:VCYTNews ReleaseVeracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
2024-02-06 08:15U:VCYTNews ReleaseVeracyte Completes Acquisition of C2i Genomics
2024-01-08 08:00U:VCYTNews ReleaseVeracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
2023-12-12 16:30U:VCYTNews ReleaseVeracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-01 16:05U:VCYTNews ReleaseReal-World Data Presented at SUO 2023 Show that Veracyte ¢ € ™s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
2023-11-29 08:30U:VCYTNews ReleaseClinical Validation Data Published in CHEST Demonstrate that Veracyte ¢ € ™s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
2023-11-22 08:30U:VCYTNews ReleaseVeracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
2023-11-07 16:05U:VCYTNews ReleaseVeracyte Announces Third Quarter 2023 Financial Results
2023-11-07 16:00U:VCYTNews ReleaseVeracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
2023-11-02 08:15U:VCYTNews ReleaseVeracyte to Participate in the Stephens Annual Investment Conference
2023-10-27 08:30U:VCYTNews ReleaseVeracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
2023-10-17 08:15U:VCYTNews ReleaseVeracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
2023-10-12 09:00U:VCYTNews ReleaseNew Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte ¢ € ™s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
2023-10-04 16:05U:VCYTNews ReleaseNew Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte ¢ € ™s Decipher Prostate Genomic Classifier
2023-09-28 16:05U:VCYTNews ReleaseNew Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte ¢ € ™s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
2023-09-28 08:15U:VCYTNews ReleaseVeracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
2023-09-27 09:00U:VCYTNews ReleaseVeracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
2023-09-21 16:05U:VCYTNews ReleaseVeracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
2023-09-07 16:05U:VCYTNews ReleaseVeracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company ¢ € ™s Tests
2023-09-06 08:15U:VCYTNews ReleaseVeracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
2023-08-29 08:15U:VCYTNews ReleaseVeracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-22 08:15U:VCYTNews ReleaseVeracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
2023-08-15 16:15U:VCYTNews ReleaseVeracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
2023-08-08 16:05U:VCYTNews ReleaseVeracyte Announces Second Quarter 2023 Financial Results
2023-08-01 08:15U:VCYTNews ReleaseStudy Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte ¢ € ™s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
2023-07-19 17:00U:VCYTNews ReleaseVeracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
2023-06-20 08:31U:VCYTNews ReleaseNew Data Suggest Veracyte ¢ € ™s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
2023-06-12 08:31U:VCYTNews ReleaseVeracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
2023-05-25 17:13U:VCYTNews ReleaseNew Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte ¢ € ™s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
2023-05-24 09:00U:VCYTNews ReleaseNew Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte ¢ € ™s Genomic Tests in Interstitial Lung Disease and Lung Cancer
2023-05-23 17:00U:VCYTNews ReleaseVeracyte to Participate in Upcoming Investor Conferences
2023-05-12 06:15U:VCYTNews ReleaseVeracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
2023-05-04 16:05U:VCYTNews ReleaseVeracyte Announces First Quarter 2023 Financial Results
2023-05-04 09:45U:VCYTNews ReleaseNew Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules